SIR-2501 is under clinical development by Sironax and currently in Phase I for Neuropathy. According to GlobalData, Phase I drugs for Neuropathy have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SIR-2501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SIR-2501 overview
SIR-2501 is under development for the treatment of neuropathies, neurodegenerative disorders and unspecified indication. The drug candidate is administered through oral route in the form of tablet.
Sironax overview
Sironax is a clinical-stage biotechnology company that discovers and develops transformational therapies. The company’s pipeline products include SIR2446 and SIR9900, SIR2, SIR3, SIR4, SIR5, SIR7(biologics) and SIR6(biologics) that treats age-related degenerative diseases. Sironax pipeline programs focus on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation, among others. The company has operations in the US, Australia and China. Sironax is headquartered in Beijing, China.
For a complete picture of SIR-2501’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
